Invested in Novel
Astute Medical's focus on novel biomarkers related to acute kidney injury (AKI) and other acute conditions has drawn interest and funding from leading health care companies. Dedicated to improving patient outcomes, our investors support Astute Medical because they recognize our expertise in developing novel diagnostic products and achieving successful commercialization.
Astute investors include De Novo Ventures, Delphi Ventures, Domain Associates, Kaiser Permanente Ventures, MPM Capital, Ortho Clinical Diagnostics and Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
Astute Medical was recognized by the Wall Street Journal as one of the Top 10 Health Care Start-Ups of 2012.1
To support or invest in novel biomarker products and clinical tools, contact Astute Medical.
Considering potential investment opportunities involving the novel biomarkers or health care fields? View what our current partners are saying:
“Astute Medical is in an excellent position to develop new diagnostic products that will improve care of seriously ill patients. We are confident in management’s ability to commercialize successful biomarker-based diagnostics given their strong track record, clinical sophistication and industry expertise.”
- Jim Blair of Domain Associates
“Astute Medical has enormous potential to identify and deliver novel diagnostic tests that address costly diseases and medical conditions. We’re delighted to work with Astute Medical and see promise in their goal of bringing innovative solutions to hospitals where poor diagnostic technologies contribute to delays and higher costs.”
- Managing Director Fred Dotzler at De Novo Ventures
1. Gormley B and Maltby E. Medical start-ups challenged by health care reform. Wall Street Journal. November 5, 2012.
http://online.wsj.com/news/articles/SB10001424052970203400604578074870506887766 Accessed May 22, 2014.